Targeting lysosomes to eradicate imatinib-resistant chronic myelogenous leukemia cells

Leukemia. 2010 May;24(5):1099-101. doi: 10.1038/leu.2010.55. Epub 2010 Apr 8.
No abstract available

Publication types

  • Letter

MeSH terms

  • Antineoplastic Agents / adverse effects*
  • Benzamides
  • Cathepsin B / antagonists & inhibitors
  • Cathepsin B / genetics
  • Cathepsin B / metabolism
  • Drug Resistance, Neoplasm*
  • Humans
  • Imatinib Mesylate
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
  • Lysosomes / metabolism*
  • Lysosomes / pathology*
  • Oligopeptides / pharmacology*
  • Piperazines / adverse effects*
  • Protein-Tyrosine Kinases / antagonists & inhibitors
  • Pyrimidines / adverse effects*
  • RNA, Small Interfering / pharmacology
  • Tumor Cells, Cultured

Substances

  • Antineoplastic Agents
  • Benzamides
  • Oligopeptides
  • Piperazines
  • Pyrimidines
  • RNA, Small Interfering
  • Imatinib Mesylate
  • Protein-Tyrosine Kinases
  • CTSB protein, human
  • Cathepsin B